Coronary Artery DiseaseSEMACADNCT06943157
Self-Efficacy and Medication Adherence in Patients With Coronary Artery Disease: A Descriptive Study
An observational study of Coronary Artery Disease, run by Hasan Kalyoncu University at 1 site in Turkey (Türkiye).
Trial summary
This descriptive study aims to examine the relationship between self-efficacy and medication adherence in individuals with coronary artery disease (CAD). The study will be conducted between March and October 2025 at Adıyaman University Training and Research Hospital with a planned sample size of 135 participants. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease
- How many people
- 150 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Mar 2025to 30 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of individuals aged 18 and older who have been diagnosed with coronary artery disease for at least one year and are being followed in cardiology or cardiovascular surgery outpatient/inpatient clinics at Adıyaman University Training and Research Hospital. All participants must be able to communicate in Turkish, have no diagnosed mental disorder, and voluntarily agree to participate in the study.
Who may be able to join
- Being 18 years of age or older
- Having been diagnosed with Coronary Artery Disease (angina pectoris, unstable angina, myocardial infarction) at least 1 year ago
- Being followed
- Being able to communicate in Turkish
- Voluntarily agreeing to participate in the study
- Having no diagnosed mental disorder
Who cannot join
- Having a primary diagnosis other than Coronary Artery Disease
- Being unable to complete the questionnaires due to mental health problems
- Providing incomplete data or withdrawing from the study
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Adiyaman University Training and Research Hospital
Adıyaman, 02040
About this study
Official title: Investigation of the Relationship Between Self-Efficacy and Adherence to Medication in Individuals With Coronary Artery Disease: A Descriptive and Correlational Study
This descriptive study aims to examine the relationship between self-efficacy and medication adherence in individuals with coronary artery disease (CAD). The study will be conducted between March and October 2025 at Adıyaman University Training and Research Hospital with a planned sample size of 135 participants. Data will be collected using a Descriptive Information Form, the Self-Efficacy for Managing Chronic Disease Scale, and the Medication Adherence Report Scale (MARS).
Read the detailed description
Coronary artery disease (CAD) remains one of the leading causes of death worldwide. Managing CAD requires long-term treatment adherence and lifestyle changes. Self-efficacy, which reflects an individual's belief in their ability to perform specific health behaviors, plays a key role in disease management. In CAD patients, high levels of self-efficacy have been associated with better treatment adherence, improved symptom management, and successful adoption of healthy behaviors.
This descriptive study is designed to investigate the relationship between self-efficacy and medication adherence in individuals diagnosed with CAD. The study will be carried out at Adıyaman University Training and Research Hospital between March and October 2025. The target population includes patients who have been diagnosed with CAD (e.g., angina pectoris, myocardial infarction) for at least one year and meet the inclusion criteria. Based on a power analysis using G*Power software (effect size f² = 0.15, α = 0.05, power = 0.90), the required sample size is calculated as 112. However, accounting for possible data loss or participant dropout, the final sample size is set at 135.
Data collection tools include:
Descriptive Information Form to assess demographic and clinical characteristics,
The 6-Item Self-Efficacy for Managing Chronic Disease Scale, validated in Turkish by İncirkuş and Özkan Nahcivan (Cronbach's alpha = 0.90),
Medication Adherence Report Scale (MARS), adapted to Turkish by Temeloğlu Şen et al. (Cronbach's alpha = 0.78).
The findings are expected to contribute to the literature and guide healthcare professionals, particularly nurses, in planning educational and counseling services to improve self-efficacy and medication adherence among CAD patients.
- Conditions
- Coronary Artery Disease
- Being tested
- No intervention
- Keywords
- Nurse, Coronary Artery Disease, Self-Efficacy, Medication Adherence
- Medical subject headings
- Coronary Artery Disease, Medication Adherence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
This is a descriptive, observational study. No intervention or experimental procedure was performed. Data were collected using self-administered questionnaires without influencing participant behavior or treatment.
| Study group | Role | What they receive |
|---|---|---|
| Coronary Artery Disease Patients | This cohort consists of individuals aged 18 and older who have been diagnosed with coronary artery disease for at least one year and are being followed in cardiology or cardiovascular surgery outpatient or inpatient clinics. Patients included are those who volunteered to participate in the study, can communicate in Turkish, and do not have any mental disorders. Receives: Other: No intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Self-efficacy score for chronic disease management
Self-efficacy levels of patients with coronary artery disease will be measured using the 6-Item Self-Efficacy Scale for Chronic Disease Management. Each item is rated from 1 to 10. The total score ranges from 6 to 60, and higher scores indicate better self-efficacy in chronic disease management.
Measured: At the time of data collection (March 2025 - October 2025)
Secondary outcomes (1)
Medication adherence score
Patients' adherence to their prescribed medication regimen will be assessed using the Medication Adherence Report Scale (MARS). The MARS scale ranges from 5 to 25, with higher scores indicating better medication adherence.
Measured: At the time of data collection (March 2025 - October 2025)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2025
- Study start1 Mar 2025
- Primary completion30 Jun 2025
- Study completion30 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hasan Kalyoncu University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zeynal KİZİR, Hasan Kalyoncu University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06943157
- Sponsor's protocol ID
- HKU-KAH-2025-01
- Acronym
- SEMACAD
- Status last verified
- Sep 2026
- First submitted
- 17 Apr 2025
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This study does not plan to share individual participant data (IPD).
Publications
Fors A, Ulin K, Cliffordson C, Ekman I, Brink E. The Cardiac Self-Efficacy Scale, a useful tool with potential to evaluate person-centred care. Eur J Cardiovasc Nurs. 2015 Dec;14(6):536-43. doi: 10.1177/1474515114548622. Epub 2014 Aug 22.
PubMed 25149667
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Relationship Between Self-Efficacy and Adherence to Medication in Individuals With Coronary Artery Disease: A Descriptive and Correlational Study
- ClinicalTrials.gov ID
- NCT06943157
- Acronym / sponsor ID
- SEMACAD / HKU-KAH-2025-01
- Conditions
- Coronary Artery Disease
- Keywords
- Nurse, Coronary Artery Disease, Self-Efficacy, Medication Adherence
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Hasan Kalyoncu UniversityUniversity, hospital or other
- Study start
- 1 Mar 2025 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 30 Jun 2025 (actual)
- First posted
- 24 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This descriptive study aims to examine the relationship between self-efficacy and medication adherence in individuals with coronary artery disease (CAD). The study will be conducted between March and October 2025 at Adıyaman University Training and Research Hospital with a planned sample size of 135 participants. Data will be collected using a Descriptive Information Form, the Self-Efficacy for Managing Chronic Disease Scale, and the Medication Adherence Report Scale (MARS).
Detailed description
Coronary artery disease (CAD) remains one of the leading causes of death worldwide. Managing CAD requires long-term treatment adherence and lifestyle changes. Self-efficacy, which reflects an individual's belief in their ability to perform specific health behaviors, plays a key role in disease management. In CAD patients, high levels of self-efficacy have been associated with better treatment adherence, improved symptom management, and successful adoption of healthy behaviors.
This descriptive study is designed to investigate the relationship between self-efficacy and medication adherence in individuals diagnosed with CAD. The study will be carried out at Adıyaman University Training and Research Hospital between March and October 2025. The target population includes patients who have been diagnosed with CAD (e.g., angina pectoris, myocardial infarction) for at least one year and meet the inclusion criteria. Based on a power analysis using G*Power software (effect size f² = 0.15, α = 0.05, power = 0.90), the required sample size is calculated as 112. However, accounting for possible data loss or participant dropout, the final sample size is set at 135.
Data collection tools include:
Descriptive Information Form to assess demographic and clinical characteristics,
The 6-Item Self-Efficacy for Managing Chronic Disease Scale, validated in Turkish by İncirkuş and Özkan Nahcivan (Cronbach's alpha = 0.90),
Medication Adherence Report Scale (MARS), adapted to Turkish by Temeloğlu Şen et al. (Cronbach's alpha = 0.78).
The findings are expected to contribute to the literature and guide healthcare professionals, particularly nurses, in planning educational and counseling services to improve self-efficacy and medication adherence among CAD patients.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Coronary Artery Disease Patients | – | Other: No interventionThis cohort consists of individuals aged 18 and older who have been diagnosed with coronary artery disease for at least one year and are being followed in cardiology or cardiovascular surgery outpatient or inpatient clinics. Patients included are those who volunteered to participate in the study, can communicate in Turkish, and do not have any mental disorders. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of individuals aged 18 and older who have been diagnosed with coronary artery disease for at least one year and are being followed in cardiology or cardiovascular surgery outpatient/inpatient clinics at Adıyaman University Training and Research Hospital. All participants must be able to communicate in Turkish, have no diagnosed mental disorder, and voluntarily agree to participate in the study.
Key inclusion criteria (6 listed)
- Being 18 years of age or older
- Having been diagnosed with Coronary Artery Disease (angina pectoris, unstable angina, myocardial infarction) at least 1 year ago
- Being followed
- Being able to communicate in Turkish
- Voluntarily agreeing to participate in the study
Key exclusion criteria (3 listed)
- Having a primary diagnosis other than Coronary Artery Disease
- Being unable to complete the questionnaires due to mental health problems
- Providing incomplete data or withdrawing from the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No interventionThis is a descriptive, observational study. No intervention or experimental procedure was performed. Data were collected using self-administered questionnaires without influencing participant behavior or treatment. | Other | Coronary Artery Disease Patients |
Primary outcome
Self-efficacy score for chronic disease management
Time frame: At the time of data collection (March 2025 - October 2025)
Self-efficacy levels of patients with coronary artery disease will be measured using the 6-Item Self-Efficacy Scale for Chronic Disease Management. Each item is rated from 1 to 10. The total score ranges from 6 to 60, and higher scores indicate better self-efficacy in chronic disease management.
1 secondary outcome
Medication adherence score
Time frame: At the time of data collection (March 2025 - October 2025)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2026.
- Background: PubMed 25149667Fors A, Ulin K, Cliffordson C, Ekman I, Brink E. The Cardiac Self-Efficacy Scale, a useful tool with potential to evaluate person-centred care. Eur J Cardiovasc Nurs. 2015 Dec;14(6):536-43. doi: 10.1177/1474515114548622. Epub 2014 Aug 22.
- Individual participant dataSharing planned: No. This study does not plan to share individual participant data (IPD).
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease, run by Hasan Kalyoncu University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Self-efficacy score for chronic disease management (time frame: At the time of data collection (March 2025 - October 2025)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06943157, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.